^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Gastric Adenocarcinoma |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer
Excerpt:
...- Patient must have histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma that is MSI-H/dMMR (microsatellite instability-high/mismatch repair deficient) as determined by one of three methods:...
Trial ID:
Source:
Title:
1429P - Pathological regression in patients with microsatellite instability (MSI) receiving perioperative atezolizumab in combination with FLOT vs. FLOT alone for resectable esophagogastric adenocarcinoma: Results from the DANTE trial of the German Gastric Group at the AIO and SAKK
Published date:
09/13/2021
Excerpt:
DANTE evaluates perioperative FLOT vs. FLOT/atezolizumab for resectable gastric or GEJ adenocarcinoma. Here, we report preliminary data for the pathological (path) regression in pts with MSI....Rate of path complete regression (TRG1a) was higher in pts with MSI than those with MSS (10/22 pts [46%] vs. 41/173 pts [24%]). Among MSI pts, rates of path complete or subtotal regression (TRG1a/b) were 80% (8/10) after FLOT/atezolizumab vs. 59% (7/12) after FLOT.
Secondary therapy:
FLOT
Trial ID: